The UK Medical Research Council (MRC) is a UK government-funded agency that supports research in前沿 biomedical sciences, including significant investments in neurodegenerative disease research.
The MRC funds fundamental and translational research across UK's universities and research institutes, supporting work on Alzheimer's disease, Parkinson's disease, Progressive Supranuclear Palsy, and related disorders.
The MRC has funded multiple major PSP research initiatives:
- Tauopathy Research: Studies on tau protein aggregation and propagation mechanisms
- Clinical Trials: Support for early-phase clinical trials in atypical parkinsonism
- Biomarker Studies: Research into fluid and imaging biomarkers for PSP
- Neuropathology: Brain bank infrastructure and tissue-based research
Key UK institutions receiving MRC funding for PSP-related research include:
- UCL Queen Square Institute of Neurology: Tau biology and clinical research
- University of Cambridge: Neurodegeneration mechanisms
- University of Oxford: Translational therapeutics
- King's College London: Biomarker development
- University of Edinburgh: Aging and neurodegeneration
The MRC collaborates with:
- National Institute for Health Research (NIHR): Clinical research infrastructure
- Alzheimer's Research UK: Joint funding initiatives
- Parkinson's UK: Collaborative research programs
- European Union Horizon Programs: International consortia
Key MRC funding schemes relevant to PSP research:
- MRC Doctoral Training Programme: Training the next generation of neurodegeneration researchers
- MRC Centenary Early Career Fellowship: Supporting early-career scientists
- MRC Strategic Skills Fellowship: Building translational research capacity
- MRC/NIHR Efficacy and Mechanism Evaluation: Clinical trial support
MRC-funded research has contributed to:
- Understanding of tau propagation in PSP
- Development of tau PET imaging tracers
- Identification of genetic risk factors
- Clinical trial infrastructure for rare neurodegenerative diseases